The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

In a groundbreaking review published in Current Molecular Pharmacology, a team led by Dr. Jhi Biau Foo from Taylor’s University unveils the pivotal role of mutant p53 (mutp53) in driving cancer ...

Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that ...

In this review, the authors present recent findings that uncover a previously unappreciated nuclear signaling hub: the PIPn-p53 signalosome. This complex not only modulates AKT activation within the ...

The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% ...

Precision medicine in endometrial cancer emphasizes molecular drivers, challenging traditional histopathologic approaches and ...

Scientists have recently shed some light on exactly why elephants, one of the biggest animals on the planet, paradoxically experience unusually low rates of cancer. The research found these remarkable ...